These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6364562)

  • 1. [Experience with endralazine in the treatment of essential hypertension].
    Dvorák I; Dvorák M; Blaha M; Kubesová H; Havlát F; Nĕmcová H
    Vnitr Lek; 1984 Jan; 30(1):42-7. PubMed ID: 6364562
    [No Abstract]   [Full Text] [Related]  

  • 2. [Endralazine in the treatment of hypertension].
    Fet'kovská N; Tison P
    Vnitr Lek; 1984 Feb; 30(2):163-8. PubMed ID: 6372236
    [No Abstract]   [Full Text] [Related]  

  • 3. [Systolic hypertension. Treatment with endralazine].
    Kilic S
    ZFA (Stuttgart); 1983 Dec; 59(34):1937-41. PubMed ID: 6367253
    [No Abstract]   [Full Text] [Related]  

  • 4. [Double-blind clinical trial of a new pyridazine and its combination with reserpine in hypertensive patients].
    Di Veroli C; Petrucci D; Romeo B
    Clin Ter; 1977 Sep; 82(6):551-67. PubMed ID: 338239
    [No Abstract]   [Full Text] [Related]  

  • 5. A double-blind study of Inderex in the treatment of essential hypertension.
    Crowe PF; Finnegan OC; Russell CJ; Varma MP
    Br J Clin Pract; 1987 Oct; 41(10):967-70. PubMed ID: 3333146
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cilazapril in essential hypertension. A placebo-controlled double-blind study to establish the dosage].
    Belz GG; Lange H; Tschollar W; Neis W
    Med Klin (Munich); 1986 Jul; 81(15-16):524-9. PubMed ID: 2946925
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cilazapril in essential hypertension. A study of one year of continuous treatment].
    Lange H; Belz GG; Tschollar W; Wolf GK
    Med Klin (Munich); 1988 Sep; 83(17):554-8. PubMed ID: 2971866
    [No Abstract]   [Full Text] [Related]  

  • 8. [Endralazine monotherapy in comparison with prazosin and hydralazine in arterial hypertension].
    Postol'nikov SF; Izotov AI; Malysheva NV
    Sov Med; 1986; (10):86-9. PubMed ID: 3544243
    [No Abstract]   [Full Text] [Related]  

  • 9. Antihypertensive effect of prizidilol.
    Jounela AJ; Honkala M; Huikuri H
    Ann Clin Res; 1984; 16(3):176-80. PubMed ID: 6383185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of endralazine (BQ-22-708) in patients with renal impairment and hypertension.
    Kingswood JC; Harrison PR; Banks RA; Higgs E; Mackenzie JC
    Postgrad Med J; 1983; 59 Suppl 3():173-6. PubMed ID: 6647204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baltimore awarded a clinical center for the study of systolic hypertension in the elderly.
    Entwisle G; Lewis C
    Md Med J; 1985 Apr; 34(4):347-8. PubMed ID: 3915528
    [No Abstract]   [Full Text] [Related]  

  • 12. [A comparison between nicardipine hydrochloride (YC-93) and trimethaphan camsylate for treatment of acute hypertension during surgery. A double blind study in 12 institutions].
    Tamai S; Mori K; Ishii S; Miyazaki M; Sumioka T; Yoshiya I; Enomoto H; Okumura F; Uchida M; Taguchi H
    Masui; 1986 Apr; 35(4):528-39. PubMed ID: 3528551
    [No Abstract]   [Full Text] [Related]  

  • 13. Antihypertensive therapy in elderly patients. Ninth interim report. The European Working Party on High Blood Pressure in the Elderly (EWPHE).
    Neth J Med; 1984; 27(4):165-70. PubMed ID: 6377103
    [No Abstract]   [Full Text] [Related]  

  • 14. Endralazine, a new peripheral vasodilator: absence of effect of acetylator status on antihypertensive effect.
    Holmes DG; Bogers WA; Wideroe TE; Huunan-Seppala A; Wideroe B
    Lancet; 1983 Mar; 1(8326 Pt 1):670-1. PubMed ID: 6132036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endralazine and acetylator phenotype.
    Meems L; Bogers WA
    Lancet; 1983 May; 1(8335):1220-1. PubMed ID: 6134015
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of once daily endralazine in hypertension.
    Wu R; Spence JD; Carruthers SG
    Eur J Clin Pharmacol; 1986; 30(5):553-7. PubMed ID: 3758143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of oxdralazine and dihydralazine in essential hypertension.
    Salvadeo A; Villa G; Segagni S; Piazza W; Criscuolo D
    Int J Clin Pharmacol Ther Toxicol; 1981 Aug; 19(8):372-6. PubMed ID: 7030978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should mild hypertension be treated? An attempted meta-analysis of the clinical trials.
    Sacks HS; Chalmers TC; Berk AA; Reitman D
    Mt Sinai J Med; 1985 Apr; 52(4):265-70. PubMed ID: 3873604
    [No Abstract]   [Full Text] [Related]  

  • 19. Double blind controlled trial of indoramin in the treatment of essential hypertension.
    Dollery DT; George DG; Lewis PJ
    Br J Pharmacol; 1972 Nov; 46(3):542P-543P. PubMed ID: 4571183
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antihypertensive effects of ecarazine hydrochloride in essential hypertension and its action on the renin-aldosterone system].
    Hata S; Yoshioka M; Kunida H
    Horumon To Rinsho; 1976 Sep; 24(9):919-34. PubMed ID: 795573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.